TEST	FUNCTION	UNITS	INCREASED	DECREASED
Hb Haemoglobin	Oxygen carrying component of blood	g/dL	 Dehydration Chronic obstructive lung disease Smoking Heart failure Renal cancer Haematological malignancy 	 Blood loss After anticancer drugs eg chemotherapy & PARP inhibitors, due to bone marrow depression Iron, folate and vitamin B12 deficiency Chronic illness Haemolysis Chronic kidney disease Haematological malignancy
Platelets (Thrombocytes)	Vital for blood coagulation.	10 ⁹ /L	 Thrombocythaemia Acute blood loss Chronic illness Certain forms of anaemia Infection Poor spleen function 	 Thrombocytopenia Infections Drugs – e.g. cytostatics Radiotherapy (rare) Immunologic disorders Haematological malignancy Cancer infiltrating bone marrow
WBC White Blood Cells / Leukocytes Differential: — Basophils — Eosinophils — Neutrophils — Lymphocytes — Monocytes	Protect the body against invading micro- organisms. The relative percentage of the various cells found in the blood is known as the (white cell) differential count.	10 ⁹ /L	 Infections Haematological malignancies Other cancers Therapy with corticosteroids Metabolic illnesses Recovering bone marrow 	 Drug – e.g. cytostatics Radiotherapy (rare) Haematological malignancy Cancer infiltrating bone marrow Immune disorders Severe infections
ESR Erythrocyte Sedimentation Rate	Non-specific indication of inflammation	mm/H	 Focus or cause of inflammation Infection Connective tissue disorder Rheumatoid arthritis Pregnancy 	 Immune disorders Congestive heart failure
Red Cell Count (Erythrocyte Count)	Delivering Oxygen to the body tissues via the circulatory system	10 ¹² /L	 Erythrocytosis Polycythaemias Smoking Renal cancer Haematological malignancy 	 Anaemia(s) Haemolysis Microangiopathies Bone marrow failure Haematological malignancy Chronic kidney disease

TEST	FUNCTION	UNITS	INCREASED	DECREASED
Bilirubin	Produced during metabolism of haem, and important part of haemoglobin. Produced and excreted by the liver. Enhanced production or diminished excretion leads to an accumulation of bilirubin causing jaundice.	μmol/L	 Jaundice / Biliary obstruction Haemolysis Advanced liver cirrhosis Acute viral hepatitis Inherited disorders or bilirubin metabolism 	
Calcium	Vital role in body's electrical processes e.g. muscle contraction, heart beat and nerve conduction. Important in bone formation and blood coagulation.	mmol/L	 Hypercalcaemia Bone metastases Multiple myeloma Hyperparathyroidism Certain drugs – e.g. diuretics Renal failure Sarcoid reactions 	 Hypocalcaemia Hypoparathyroidism Lack of vitamin D Malabsorption Renal insufficiency Renal wasting -cytotoxic drugs e.g. cisplatin Tumour lysis syndrome
Chloride	Changes in chloride content indicate changes in other electrolytes in the body	mmol/L	HyperchloraemiaHyperventilationDehydration	 Hypochloraemia Vomiting and diarrhoea Metastatic alkalosis – secondary to low sodium
Creatinine	Principle parameter used for determination of renal function	µmol/L	Renal failure of all causes	 If very low weight, muscle bulk
Glucose	The main energy source for the body.	mmol/L	Hyperglycaemia • Diabetes mellitus • Severe stress • Steroids	Hypoglycaemia • Insulin overdose • Insulinoma • Liver failure • Adrenal insufficiency • Severe sepsis
LDH (lactate dehydrogenase)	Present in all organs. Is a non-specific measurement of tissue breakdown and injury. It can be used to monitor certain malignancies such as Hodgkin's disease.	IU/L	 Hodgkin's Lymphoma Liver disease Haemolysis Muscle disease Myocardial infarction Pancreatitis Encephalitis and Meningitis 	
Phosphorus	Major component of mineral phase of the bone. Involved in almost all metabolic processes.	mmol/L	 Hyperphosphataemia Renal failure Hypoparathyroidism Acromegaly Tumour lysis syndromes 	Hypophosphataemia • Hyperparathyroidism • Hypomagnesaemia • Alcoholism

TEST	FUNCTION	UNITS	INCREASED	DECREASED
Potassium	Important role in a number of metabolic processes.	mmol/L	 Hyperkalaemia Renal insufficiency Potassium sparing diuretics and other drugs Tissue damage Addison's disease Metabolic acidosis 	 Hypokalaemia Excessive potassium loss – e.g. excessive vomiting or diarrhoea Diuretics Certain chemotherapeutic agents – e.g. antibiotics
Sodium	Most prevalent electrolyte in the plasma. Sodium metabolism is very closely interrelated with water metabolism.	mmol/L	 Hypernatraemia Impaired water intake Excessive water loss – e.g. sweating, loss by the kidneys (diabetes insipidus and diabetes mellitus) or gastrointestinal loss (vomiting, diarrhoea) 	 Hyponatraemia Cancer Infection Head injury SIADH – syndrome of inappropriate ADH secretion - seen with drugs such as cyclophosphamide and vincristine Ectopic ADH secretion in small cell lung cancer (SCLC) Vomiting, diarrhoea Advanced heart failure Use of diuretics Antibiotics and other drugs
Urate	Product of DNA metabolism and can be grossly elevated after massive cell death caused by cytotoxic drugs. Excreted by the kidneys. Deposition in the joints causes gout.	Mmol/L	 Following chemotherapy (when no preventative measures have been taken) Tumour lysis syndrome Renal insufficiency 	Hyperthyroidism Myeloma
Urea	End product of metabolism of proteins in the body. Excreted by the kidneys and together with Creatinine is a measure of renal function.	Mmol/L	Renal diseaseDehydration causing renal insufficiency	Ectopic ADH secretion in small cell lung cancer (SCLC)

TEST	FUNCTION	UNITS	INCREASED	DECREASED
ALP (alkaline phosphatase)	Intracellular enzyme – hydrolyses synthetic phosphate esters. Produced by many tissues – especially bone, intestine, liver and placenta. Is excreted in bile.	IU/L	 Obstruction of the common bile duct Liver disease Increased osteoblast activity (may be a result of osteoblastic bone metastases or normal growth) 	Malnutrition
ALT (alanine aminotransferase)	Present primarily in the liver, to the lesser extent in the kidneys and skeletal muscle.	IU/L	 Liver cell damage – e.g. metastases 	
AST (aspartate aminotransferase)	Present in all body tissues especially heart, liver and skeletal muscle. Released into the blood in excessive amount when these are damaged.	IU/L	 Liver cell damage – e.g. metastases Myocardial infarction 	
GGT (Gamma-glutamyl transpeptidase)	Present in many tissues. Involved in transfer of amino acids into cells. Measure of hepatobiliary disease	IU/L	Liver metastasesAll hepatobiliary disordersAlcohol abuse	

NB. ALT /ALT both raised = transaminitis, Hepatic injury of any cause eg

- Infections
- Drugs
- Metastases

LABORATORY TESTS

CARDIAC TESTS

TEST	FUNCTION	UNITS	INCREASED	DECREASED
LVEF	Cardiac function	%	Good Function	Poor Function
Left Ventricular Ejection	Potential damage from use of			
Fraction	Herceptin and Anthracyclines (eg			
	Doxorubicin)			

PULMONARY FUNCTION TESTS (PFTs)

TEST	FUNCTION	UNITS	INCREASED	DECREASED
DLCO	Diffusion Capacity Measure of how easily oxygen passes from lungs into blood	mL/mmHg/min	Lung haemorrhage	 Indicates a diffusion disorder such as Pulmonary Fibrosis Chronic obstructive pulmonary disease
TLCO	Diffusion Capacity (This value can be considered the same as DLCO)	mL/mmHg/min		
FEV1/FVC ratio (FEV1%)	Spirometry. This test is a measure of volume and capacity of exhaled air. This is given as a true value (e.g. 99.00) and a %. As this is a ratio of a true value as a % of average the % can be > 100	% of normal	Increased in obstructive lung diseaseChronic obstructive pulmonary diseaseAsthma	Decreased in restrictive lung disease Pulmonary fibrosis
FEV1	Spirometry. Measure of exhalation volume in 1 second. This is given as a true value (e.g. 9.00) and a % of normal. As the true value can be above average the % can be > 100	% of normal		 Chronic obstructive pulmonary disease Asthma

LABORATORY TESTS

THYROID FUNCTION TESTS

TEST	FUNCTION	UNITS	INCREASED	DECREASED
T4 Thyroxine	Hormone secreted by the Thyroid. It regulates the rate of metabolic processes in the body and influences physical development	mmol/L	Hyperthyroidism • Autoimmune • Thyroid adenoma • Thyroiditis • Teratoma • Pituitary adenoma	 Hypothyroidism Autoimmune Iodine deficiency Pituitary failure Drugs
TSH Thyroid Stimulating Hormone	Regulates the endocrine function of the Thyroid gland	mU/L	Hypothyroidism	Hyperthyroidism

GONAD FUNCTION TESTS

TEST	FUNCTION	UNITS	INCREASED	DECREASED
FSH Follicle Stimulating Hormone	Hormone in the endocrine system. FSH regulates the development, growth, pubertal maturation, and reproductive processes of the body - (acts synergistically with LH)	IU/L	Post-menopausePituitary tumour	 Pregnancy Rapid weight loss Pituitary failure
LH Luteinizing Hormone ICSH (interstitial cell- stimulating hormone)	In females this hormone triggers ovulation and in men produces testosterone	mIU/mL	Post-menopausePolycystic ovarian syndrome	Pituitary failure
Oestradiol	Sex hormone found in both sexes. Regulates female organ and tissue development. In males it regulates the life cycle of sperm cells. Also has effects on bone structure, protein synthesis in the liver, neuroprotective function in the brain, blood flow in blood vessels, and oncogene activation in breast and endometrial cancers	ng/dL	 Liver cirrhosis Adrenal cancer Testicular tumour 	 Ovarian failure Post-menopause Polycystic ovarian syndrome Pituitary failure
Testosterone	Male reproductive organ and tissue development, muscle development, bone mass and body hair	ng/dL	Testicular tumourOvarian cancer	Hypopituitarism
Sperm Count	Concentration of sperm	10 ⁶ /mL		

TEST	FUNCTION	UNITS	INCREASED	DECREASED
Total Cholesterol	 Membrane production 	mmol/L or mg/dL	Hypercholesterolaemia • Kidney disease • Diabetes • Alcohol • Overweight	Hypocholesterolaemia
Triglycerides	 An ester containing glycerol and fatty acids 	mmol/L or mg/dL	Cardiovascular Disease	
HDL –C - High-density lipoprotein cholesterol	 Lipid transportation (known as good cholesterol) 	mmol/L or mg/dL		
LDL-C - Low-density lipoprotein cholesterol	 Lipid transportation (known as bad cholesterol) 	mmol/L or mg/dL	Hypercholesterolaemia • Kidney disease • Diabetes • Alcohol • Overweight	

LABORATORY TESTS

CREATINE PHOSPHOKINASE

TEST	FUNCTION	UNITS	INCREASED	DECREASED
Creatine Phosphokinase	An enzyme that is present in various tissues and cell types (e.g. skeletal and heart muscle). Damage to these tissues and cells releases this enzyme so that it becomes detectable in the blood. This enzyme is thus a marker for certain types of tissue/cell damage.	U/L	 Stroke Inflammatory muscle disorders Heart attack Rhabdomyolysis 	

TEST	FUNCTION	UNITS	INCREASED	DECREASED
Serum IgA	Antibody that forms	g/L	Myeloma	Immunodeficiency
lg = Imunnoglobulin	immunity of the mucosa		Infection	Gonorrhoea
IgM	Primary antibody against A	g/L	Liver disease	Hereditary
	and B antigens on red blood		Infection	Myeloma
	cells		Myeloma	
IgD	Main role in the signalling	g/L	Infection	Immunodeficiency
	pathway for B-cell activation		Myeloma	
IgG	Antibody of secondary	g/L	Infection	Immunodeficiency
	immune response		Myeloma	
IgE	Antibody associated with	g/L	Allergy	Immunodeficiency
	allergy and immune response		Asthma	
	to parasites		Myeloma (rare)	
Kappa Serum Free Light Chain	Polypeptide subunit of an B	mg/L	Myeloma	
(3.30 – 19.40)	Lymphocyte (antibody) that			
	binds with an antigen			
Lambda Serum Free Light	Polypeptide subunit of an B	mg/L	Myeloma	
Chain	Lymphocyte (antibody) that			
(5.71 – 26.30)	binds with an antigen			
Kappa to Lambda Ratio	B Lymphocytes express only	Ratio or	Neoplasm	Bone marrow function impairment
(Serum ratio = 2:1	one type of light chain. This	decimal	Inflammatory condition (proliferation of	
Free Light Chain ratio = 1:1.5)	ratio is an indication of clonal		polyclonal FLCs)	
Or as decimal 0.26 – 1.65)	disease		 Biclonal gammopathies of different FLC 	
			types	
Serum Paraprotein	Abnormal immunoglobulin	g/L	Myeloma	
	(Ig) or light chain secreted in			
	excess by plasma cells (white			
	blood cell type) during			
	myeloma (myeloma is a			
	plasma cell cancer)			

TEST	FUNCTION	INCREASED
AFP (alpha-fetoprotein)	Synthesised by the liver, yolk sac and GI tract of the human foetus. Reaches peak plasma concentration at 12 – 15 weeks gestation, decreasing to normal adult levels 6 – 12 months after birth. AFP has prognostic implication. During therapy the rate of decline predicts the effectiveness of therapy. Rising level is direct evidence of tumour progression.	 CANCER RELATED Embryonal and teratocarcinomas of the ovary and testes Extragonadal germ cell tumours Hepatoma and other liver diseases Cancer of pancreas, stomach, colon and lung (less frequent) OTHER REASONS Ataxia telangiectasia
CA125 (carbohydrate antigen 125)	Monoclonal antibody which recognises a certain antigen and is used as a marker for patients with ovarian cancer. A persistently elevated CA125 following oophorectomy for suspected stage I ovarian carcinoma is definite evidence of residual disease.	 CANCER RELATED Ovarian cancer Advanced intra-abdominal (non-ovarian) malignancy Ascitic fluid – due to cancer (or other disease) OTHER REASONS First trimester of pregnancy Endometriosis Cirrhosis Health controls
CEA (carcinoembryonic antigen)	Normally secreted during the second to sixth month of gestation. In non-smoking adults serum levels are 2.5ng/ml, smokers have normal levels up to 5ng/ml. Principle role of this marker is to monitor the response to treatment. A complete response to surgery, radiotherapy or chemotherapy should bring an elevated CEA to normal within one month of treatment. A persistent or increasing elevation is highly suggestive of residual or recurrent tumour.	CANCER RELATED • Colon cancer • Pancreatic cancer • Gastric cancer • Lung cancer • Breast cancer OTHER REASONS • Inflammatory bowel disease
CT (calcitonin)	Normally secreted by the parafollicular cells of the thyroid gland and serves as an excellent marker of tumours developed from these cells (medullary carcinomas). Calcitonin is also secreted by a variety of other tumours.	 CANCER RELATED Medullary thyroid cancer Disseminated breast cancer Lung cancer
ER and PgR (estradiol & progesterone receptor)	The presence of ER and/or PgR receptor activity in breast tumour tissue is an indicator of its hormone dependency. Both markers are now frequently used in clinical practice to select, to each patient individually, the most appropriate form of systemic adjuvant or palliative therapy. The presence of ER and PgR is an important prognostic factor that is correlated with a better clinical outcome.	CANCER RELATED Breast cancer

TEST	FUNCTION	INCREASED
hCG	Hormone secreted by the placenta and consisting of α and β subunits. The β subunits	CANCER RELATED
(human chorionic	is normally present in maternal serum during pregnancy, however, presence in non-	Trophoblastic tumours (Choriocarcinoma, hydatidiform
gonadotrophin)	pregnant females and males is indicative of cancer. Its level has prognostic importance	mole)
	and a decrease marks an effect of therapy.	Germ cell tumour of the testes
		OTHER REASONS
		Pregnancy
РАР	Enzyme produced by the prostatic epithelium. Less sensitive and specific than PSA	CANCER RELATED
(prostatic acid phosphatise)	levels with regards to prostatic cancer.	Prostate cancer
		OTHER REASONS
		Benign prostatic hypertrophy
PSA	Secreted exclusively by prostatic epithelial cells. Its serum concentration increased in	CANCER RELATED
(prostate-specific antigen)	men with prostatic disease.	Prostate cancer
		OTHER REASONS
		Benign prostatic hypertrophy
Тg	Increased in patients with thyroid disease. Increased Tg in patients with metastatic	CANCER RELATED
(thyroglobulin)	carcinoma of the thyroid is an indication of tumour tissue being present in the body.	Thyroid cancer
		OTHER REASONS
		Hyperthyroidism
		Dysplastic struma